AGTC thus received a $2-million milestone payment in a collaboration to develop a gene therapy for neovascular AMD.
AGTC (Applied Genetic Technologies Corporation) received a $2-million milestone payment from Genzyme as the company successfully transferred its adeno-associated virus (AAV) vector production technology to Genzyme.
AGTC and Genzyme are jointly developing a gene therapy product for the treatment of neovascular age-related macular degeneration (AMD). Genzyme thus has access to AGTC’s vector production expertise along with rights to certain intellectual property for the use of AAV vectors to deliver genes to patients. These rights include access to AGTC’s high-yield manufacturing technology for AAV vectors.
